Niclosamide Encapsulated Polymeric Nanocarriers for Targeted Cancer Therapy

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 9

PMID 35528602

Authors

Nishant Kumar Jain

Prabhuraj R S

M C Bavya

Rajendra Prasad

Rajdip Bandyopadhyaya

V G M Naidu

Rohit Srivastava

Affiliations

Soon will be listed here.

Abstract

Localized cancer rates are on an upsurge, severely affecting mankind across the globe. Timely diagnosis and adopting appropriate treatment strategies could improve the quality of life significantly reducing the mortality and morbidity rates. Recently, nanotherapeutics has precipitously shown increased efficacy for controlling abnormal tissue growth in certain sites in the body, among which ligand functionalized nanoparticles (NP) have caught much attention for improved survival statistics active targeting. Our focus was to repurpose the antihelminthic drug, niclosamide (NIC), which could aid in inhibiting the abnormal growth of cells restricted to a specific region. The work here presents a one-pot synthesis of niclosamide encapsulated, hyaluronic acid functionalized core-shell nanocarriers [(NIC-PLGA NP)HA] for active targeting of localized cancer. The synthesized nanocarriers were found to possess spherical morphology with mean size of 150.8 ± 9 nm and zeta potential of -24.9 ± 7.21 mV. The encapsulation efficiency was found to be 79.19 ± 0.16% with a loading efficiency of 7.19 ± 0.01%. The nanohybrids exhibited extreme cytocompatibility upon testing with MDA-MB-231 and L929 cell lines. The rate of cancer cell elimination was approximately 85% with targeted cell imaging results being highly convincing. [(NIC-PLGA NP)HA] demonstrates increased cellular uptake leading to a hike in reactive oxygen species (ROS) generation, combating tumour cells aiding in the localized treatment of cancer and associated therapy.

Citing Articles

Immobilization of Olive Leaf Extract with Chitosan Nanoparticles as an Adjunct to Enhance Cytotoxicity.

Ozdamar B, Surmeli Y, Sanli-Mohamed G ACS Omega. 2023; 8(32):28994-29002.

PMID: 37599944 PMC: 10433347. DOI: 10.1021/acsomega.3c01494.

Repurposing Anthelmintics: Rafoxanide- and Copper-Functionalized SBA-15 Carriers against Methicillin-Resistant .

Ramirez-Hernandez M, Norambuena J, Hu H, Thomas B, Tang C, Boyd J ACS Appl Mater Interfaces. 2023; 15(14):17459-17469.

PMID: 36975176 PMC: 10257252. DOI: 10.1021/acsami.2c19899.

Niclosamide-loaded nanoparticles disrupt Candida biofilms and protect mice from mucosal candidiasis.

Sutar Y, Nabeela S, Singh S, Alqarihi A, Solis N, Ghebremariam T PLoS Biol. 2022; 20(8):e3001762.

PMID: 35976859 PMC: 9385045. DOI: 10.1371/journal.pbio.3001762.

Polymer-Based Hybrid Nanoarchitectures for Cancer Therapy Applications.

Kumar A, Sharipov M, Turaev A, Azizov S, Azizov I, Makhado E Polymers (Basel). 2022; 14(15).

PMID: 35893988 PMC: 9370428. DOI: 10.3390/polym14153027.

Airway Delivery of Hydrogel-Encapsulated Niclosamide for the Treatment of Inflammatory Airway Disease.

Ousingsawat J, Centeio R, Cabrita I, Talbi K, Zimmer O, Graf M Int J Mol Sci. 2022; 23(3).

PMID: 35163010 PMC: 8835663. DOI: 10.3390/ijms23031085.

References

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

Goodman L, Wintrobe M . Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 2010; 132:126-32. DOI: 10.1001/jama.1946.02870380008004. View

George L, Bavya M, Vimal Rohan K, Srivastava R . A therapeutic polyelectrolyte-vitamin C nanoparticulate system in polyvinyl alcohol-alginate hydrogel: An approach to treat skin and soft tissue infections caused by Staphylococcus aureus. Colloids Surf B Biointerfaces. 2017; 160:315-324. DOI: 10.1016/j.colsurfb.2017.09.030. View

Singh A, Talekar M, Tran T, Samanta A, Sundaram R, Amiji M . Combinatorial approach in the design of multifunctional polymeric nano-delivery systems for cancer therapy. J Mater Chem B. 2020; 2(46):8069-8084. DOI: 10.1039/c4tb01083c. View

Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411(6836):494-8. DOI: 10.1038/35078107. View

Mattheolabakis G, Milane L, Singh A, Amiji M . Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015; 23(7-8):605-18. DOI: 10.3109/1061186X.2015.1052072. View

Xu L, Fukumura D, Jain R . Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem. 2001; 277(13):11368-74. DOI: 10.1074/jbc.M108347200. View

Costa D, Mendes L, Torchilin V . The effect of low- and high-penetration light on localized cancer therapy. Adv Drug Deliv Rev. 2018; 138:105-116. DOI: 10.1016/j.addr.2018.09.004. View

Kim J, Moon M, Kim D, Heo S, Jeong Y . Hyaluronic Acid-Based Nanomaterials for Cancer Therapy. Polymers (Basel). 2019; 10(10). PMC: 6403826. DOI: 10.3390/polym10101133. View

10.

Shuai K, Horvath C, Huang L, Qureshi S, Cowburn D, Darnell Jr J . Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell. 1994; 76(5):821-8. DOI: 10.1016/0092-8674(94)90357-3. View

11.

Simon H, Levi-Schaffer F . Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 2001; 5(5):415-8. DOI: 10.1023/a:1009616228304. View

12.

Wolny P, Banerji S, Gounou C, Brisson A, Day A, Jackson D . Analysis of CD44-hyaluronan interactions in an artificial membrane system: insights into the distinct binding properties of high and low molecular weight hyaluronan. J Biol Chem. 2010; 285(39):30170-80. PMC: 2943326. DOI: 10.1074/jbc.M110.137562. View

13.

Rizzoli G, Gregio L, Mazzucco A, Stritoni P, Fracasso A, Brumana T . Determinants of late survival of 105 patients operated for dissection of the aorta. Eur J Cardiothorac Surg. 1988; 2(1):18-24. DOI: 10.1016/1010-7940(88)90091-7. View

14.

van Tonder E, Maleka T, Liebenberg W, Song M, Wurster D, de Villiers M . Preparation and physicochemical properties of niclosamide anhydrate and two monohydrates. Int J Pharm. 2004; 269(2):417-32. DOI: 10.1016/j.ijpharm.2003.09.035. View

15.

Cadenas E . Mitochondrial free radical production and cell signaling. Mol Aspects Med. 2004; 25(1-2):17-26. DOI: 10.1016/j.mam.2004.02.005. View

16.

Lu J, Wang X, Marin-Muller C, Wang H, Lin P, Yao Q . Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009; 9(4):325-41. PMC: 2701163. DOI: 10.1586/erm.09.15. View

17.

Tao H, Zhang Y, Zeng X, Shulman G, Jin S . Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med. 2014; 20(11):1263-9. PMC: 4299950. DOI: 10.1038/nm.3699. View

18.

Huang G, Huang H . Application of hyaluronic acid as carriers in drug delivery. Drug Deliv. 2018; 25(1):766-772. PMC: 6058522. DOI: 10.1080/10717544.2018.1450910. View

19.

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

20.

Amorim S, Soares da Costa D, Freitas D, Reis C, Reis R, Pashkuleva I . Molecular weight of surface immobilized hyaluronic acid influences CD44-mediated binding of gastric cancer cells. Sci Rep. 2018; 8(1):16058. PMC: 6207784. DOI: 10.1038/s41598-018-34445-0. View